financial guidance

The company missed analyst estimates on its top line, but beat analyst estimates for adjusted earnings per share and raised its adjusted EPS guidance for FY 2017.

The company credited its molecular diagnostics and international businesses as drivers of new growth.

Qiagen's revenues grew 6 percent at constant exchange rates to $349.0 million, besting the average Wall Street estimate of $346.6 million.

The company, which beat analyst estimates on both the top and bottom lines, said completed Cologuard test volume rose 149 percent to 135,000 tests.

The change comes amid lower than expected revenues for the first half of this year, as well as an anticipated continued lack of reimbursement coverage in the US. 

The firm said today that it received a notice that it is out of compliance with a rule requiring timely filings with the US Securities and Exchange Commission.

The firm saw 6 percent growth in its life sciences and applied markets group and 13 percent growth in its diagnostics and genomics group during the quarter.

The firm said revenues for its discovery and analytical solutions business rose 1 percent year over year while revenues from diagnostics rose 8 percent.

The company missed analyst estimates on the top line, but beat expectations for loss per share during the quarter.

The company posted a 3 percent increase in molecular diagnostics sales at constant exchange rates, and a 3 percent decline in instrument sales.